Yuriko Ninomiya

Learn More
Blonanserin was developed as an antipsychotic drug in Japan and approved for the treatment of schizophrenia. It belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and acts as an antagonist at dopamine D2, D3, and serotonin 5-HT2A receptors. Blonanserin has low affinity for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 receptors, but(More)
AIMS The purpose of this study was to evaluate the long-term effectiveness and safety of blonanserin, a second-generation antipsychotic drug developed in Japan, in patients with first-episode schizophrenia. METHODS Twenty-three antipsychotic-naïve patients with first-episode schizophrenia were treated within an open-label, 1-year, prospective trial of(More)
Introduction: Electroconvulsive therapy (ECT) and antipsychotic polypharmacy (APP) have been utilized frequently for patients with schizophrenia, particularly for treatment-resistant cases in clinical practice. The prevalence of APP and high-dose antipsychotics is high in Japan, although they are associated with an increased risk for various adverse(More)
  • 1